Moderate

Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease

Retrieved on: 
Thursday, February 9, 2023
NMPA, Moderate, Luke Fildes, Baylor, Pulmonary hypertension, Quality of life, MVPA, Patient, Partnership, National Medical Products Administration, Therapy, Pharmaceutical industry, IND

The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.

Key Points: 
  • The study will utilize Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s regional partner, Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.
  • “We are delighted to expand our clinical program with the aim of bringing INOpulse to patients in need in Greater China,” said Peter Fernandes, Bellerophon’s Chief Executive Officer.
  • “INOpulse has the potential to become the first therapy to treat an fILD population that includes patients at low-, intermediate- and high-risk of pulmonary hypertension.
  • “INOpulse has significant potential in treating various diseases associated with pulmonary hypertension and the clearance of this IND brings us one step closer to a new treatment option for the underserved fILD patient community in Greater China.”

Perceptyx Adds More Than 100 New Enterprise Customers, Including Gannett and Banner Health

Retrieved on: 
Wednesday, January 25, 2023
Google Workspace, TEAMS, HCM, AI, Gold, Moderate, Cultivation, HR, Microsoft, Pulse, Assessment, Partnership, Gannett, Banner Health, Gartner, Microsoft Teams, Slack, Growth, Culture, Engineering, Management

The company’s platform was selected by more than 100 top enterprise brands across multiple industries, from healthcare and technology to retail and hospitality, in the US and Europe.

Key Points: 
  • The company’s platform was selected by more than 100 top enterprise brands across multiple industries, from healthcare and technology to retail and hospitality, in the US and Europe.
  • New customers include Banner Health, a 30-hospital health system and one of the largest employers in the U.S. with over 50,000 employees and Gannett the largest U.S. newspaper publisher based on daily circulation.
  • “Today’s workforces are more diverse and distributed than ever before, with teams frequently spanning five generations, multiple geographies, and countless different backgrounds.
  • Employers have realized that they can’t truly understand the needs of their employees with a one-size-fits-all approach,” said John Borland, CEO of Perceptyx.

IMOU Wins the First Places in KITTI 2D Object Detection (Pedestrian) , Multi -object Tracking (Pedestrian & Car) Evaluations

Retrieved on: 
Monday, January 16, 2023
Algorithm, Radical behaviorism, Karlsruhe Institute of Technology, Distortion, HOTA, AI, Household, Artificial intelligence, Pedestrian, Data analysis, TBD, Moderate, Medical imaging, Medical device

Recently, IMOU, the smart home brand in China, wins the first places in KITTI 2D object detection of pedestrian, multi-object tracking of pedestrian and car evaluations.

Key Points: 
  • Recently, IMOU, the smart home brand in China, wins the first places in KITTI 2D object detection of pedestrian, multi-object tracking of pedestrian and car evaluations.
  • It scores 57.15% high-order tracking accuracy (HOTA) for multi-object tracking of pedestrian, 82.08% (HOTA) for multi-object tracking of car, and 82.77% (Moderate) for 2D object detection of pedestrian.
  • For multi-object tracking, IMOU optimizes object detection, re-identification, object correlation, and other modules based on the TBD framework to improve the overall performance.
  • KITTI is used for the evaluations of stereo vison, optical flow, scene flow, visual odometry, object detection, target tracking, road detection, semantic and instance segmentation.

1 in 3 Organizations Does Not Provide Any Cybersecurity Training to Remote Workers Despite a Majority of Employees Having Access to Critical Data

Retrieved on: 
Thursday, January 12, 2023
Internet Security Awareness Training, Moderate, Organization, Climate, Smartphone, Risk, Education, Knowledge, Research, Medical device, Risk management

Despite the current lack of training and employees feeling ill-equipped, almost half (44%) of respondents said their organisation plans to increase the percentage of employees that work remotely.

Key Points: 
  • Despite the current lack of training and employees feeling ill-equipped, almost half (44%) of respondents said their organisation plans to increase the percentage of employees that work remotely.
  • "Traditional methods of controlling and securing company data aren't as effective when employees are working in remote locations and greater responsibility falls on the individual.
  • Hofmann commented: "Increasing remote working cybersecurity measures is particularly important in the current climate, as cybercriminals are becoming smarter and using remote working to their advantage.
  • It's clear that having both security awareness training and investment in endpoint management systems are vital to have robust remote cybersecurity for organizations.

STRATA Skin Sciences Announces Poster Accepted at ODAC Dermatology, Aesthetic & Surgical Conference

Retrieved on: 
Friday, January 13, 2023
Moderate, Acne, Face, MHS, Lake, Safety, MD, PPT, Strata Skin Sciences, Conference, Marketing, Comedo, DRS, Red, Male, Pigment, Aesthetics, Female, Skin, Pharmaceutical industry, Medical imaging, Cosmetics, Dermatology, Patient

The objective of the clinical assessments was to evaluate, via photographs, changes in visible acne lesions and skin texture after a series of tailored photopneumatic therapy (PPT) treatments delivered to patients with mild-moderate acne.

Key Points: 
  • The objective of the clinical assessments was to evaluate, via photographs, changes in visible acne lesions and skin texture after a series of tailored photopneumatic therapy (PPT) treatments delivered to patients with mild-moderate acne.
  • Patients were eligible to receive 4-6 in office photopneumatic treatments 1-2 weeks apart for 15 minutes per treatment.
  • The duration of the treatments were tailored to each patient’s skin type, severity of acne and type of acne lesions.
  • Munavalli, Smith and Smith for their contributions,” stated Bob Moccia, President and Chief Executive Officer of STRATA Skin Sciences.

Zscaler Becomes Member of Joint Cyber Defense Collaborative to Enhance Cybersecurity Posture of U.S. and Strategic International Partners

Retrieved on: 
Monday, December 19, 2022
Moderate, Ecosystem, ZS, CISA, High, Computer security, Telemetry, Private sector, Risk, SAN, Public sector, FedRAMP, Federation, Cybersecurity and Infrastructure Security Agency, Internet, Government, Joint, Software as a service, Intelligence, Risk management, Cryptocurrency, Zscaler

“We founded Zscaler with the vision to create a modern cloud-native architecture for the seamless and secure exchange of information,” said Jay Chaudhry, CEO, chairman and founder of Zscaler. “Today, digital transformation has accelerated organizations’ move to cloud-based SaaS models and the internet is now the new corporate network -- rendering 30 years of networking and security principles ineffective. We are honored to be working with JCDC to leverage the threat intelligence in Zscaler’s zero trust platform to help stop large-scale cyberattacks, prevent data exfiltration, and block debilitating ransomware attempts.”

Key Points: 
  • (NASDAQ: ZS), the leader in cloud security, today announced its membership in the Joint Cyber Defense Collaborative (JCDC), underscoring the company’s commitment to improving the nation’s cyber resiliency.
  • JCDC, established by the Cybersecurity and Infrastructure Security Agency (CISA) in 2021, leads the development and implementation of joint cyber defense plans and operations through critical partnerships with the private sector, Federal government and state, local, tribal and territorial governments.
  • Zscaler will work with JCDC to enhance the collective cybersecurity posture of the United States and strategic international partners.
  • Additionally, Zscaler will participate in future cyber strategy planning with JCDC and its members.

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

Retrieved on: 
Wednesday, December 7, 2022
NMS, Depression, Metoclopramide, Absorption, Suicidal ideation, EPS, Fatigue, Physiology, Evoke, Tardive dyskinesia, Gastroparesis, MBA, Neuroleptic malignant syndrome, Creatinine, COVID-19, Parkinsonism, Dysgeusia, Food, FDA, Patent, Risk, Internal bleeding, Perforation, Methemoglobinemia, Hypersensitivity, Extrapyramidal symptoms, Water, Moderate, Hypertension, Neoplasm, Orange Book, Bronchospasm, Epilepsy, Liver, Seizure, Patient, Kidney, United, Catecholamine, TD, Headache, Pheochromocytoma, Suicide, Stomach, Hyperprolactinaemia, History, CYP2D6, Pharmaceutical industry, Aroma compound, Residential care, Generic drug, EU
Key Points: 

    Programmable Logic Controllers Sourcing and Procurement Market Will Have an Incremental Spend of USD 1,163.07 Million: SpendEdge

    Retrieved on: 
    Tuesday, December 13, 2022
    Intelligence, Programmable logic device, Iron Mountain (company), Programmable logic controller, Moderate, Pet recovery service, Oil

    Vulnerability Management Sourcing and Procurement Report :Vulnerability Management Procurement Market, prices will increase by 4%-6% during the forecast period and suppliers will have Moderate bargaining power in this market.

    Key Points: 
    • Vulnerability Management Sourcing and Procurement Report :Vulnerability Management Procurement Market, prices will increase by 4%-6% during the forecast period and suppliers will have Moderate bargaining power in this market.
    • Outplacement Services - Sourcing and Procurement Intelligence Report :This report offers key advisory and intelligence to help buyers identify and shortlist the most suitable suppliers for their Outplacement Services requirements.
    • To access the definite purchasing guide on the Programmable Logic Controllers that answers all your key questions on price trends and analysis:
      Am I paying/getting the right prices?
    • Register for a free trial today and gain instant access to 1,200+ market research reports.

    Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

    Retrieved on: 
    Monday, November 28, 2022
    Biotechnology, Health, Radiology, Pharmaceutical, Clinical Trials, NYSE American, RA, History, Technetium-99m, Macrophage, Biopharmaceutical, Rheumatology, Health, Physician, Joint, Moderate, Drug Quality and Security Act, Annual report, Rheumatoid arthritis, Inflammation, Disease, NYSE, Risk, Research, Coronavirus, FDA, Pharmaceutical industry, Medical imaging, Patient

    This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.

    Key Points: 
    • This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.
    • These macrophage density changes may be observable weeks before disease modification can be detected with standard clinical assessments.
    • The NAV3-33 Phase 3 trial involves Tc99m tilmanocept imaging in participants with RA who are about to begin anti-TNF therapy.
    • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

    Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

    Retrieved on: 
    Monday, November 14, 2022
    FDA, Clinical trial, Trial of the century, Survival, Sarcoidosis, Interstitial lung disease, Data monitoring committee, Paul Fildes, PVR, Actigraphy, DMC, Moderate, Therapy, Patient, Pulmonary hypertension, Hepatic artery proper, Particle-size distribution, Safety, Security (finance), Food and Drug Administration, Annual report, Tesa SA, Research, Ino, Diagnosis, Public expenditure, Food, Pharmaceutical industry, MVPA, Bellerophon

    WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022.

    Key Points: 
    • WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (Bellerophon or the Company), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the third quarter ended September 30, 2022.
    • REBUILD Phase 3 Study: Phase 3 REBUILD registrational study enrollment of INOpulse for the treatment of fILD is approaching completion.
    • The reduced study size is 140 fILD patients who will be treated with either INOpulse at a dose of iNO45 or a placebo.
    • The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.